Bladder Cancer: More Questions Than Answers With pCR Endpoint

 
• By Derrick Gingery
  
Bladder-cancer-cells
Validating pCR as a surrogate endpoint could help advance drug development in muscle-invasive bladder cancer. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D